Ryman Healthcare (RYM) / HY26

RYM's first positive FCF in a decade masks a $40.2m PBT loss

Balance sheet reset is structurally positive, but operating earnings remain deeply negative while GAAP losses obscure the transformation narrative.

Release date
27 November 2025
Published
21 April 2026

What changed

Revenue grew 13% to $413.8m in HY26 from $366.3m in HY25, with New Zealand villages (76% of revenue) and Australia villages (24%) both contributing. Despite that top-line growth, reported PBT swung to a loss of $40.2m from a profit of $174.8m a year earlier — a deterioration of $215m — driven primarily by the absence or reversal of investment property fair value gains that flattered HY25. NPAT followed to a loss of $45.2m from a profit of $94.4m.

The most striking balance sheet development is the $928m reduction in gross borrowings to $1.663b, materially completing the "balance sheet reset" management flagged. Net debt improved to approximately $1.654b. Trade receivables collapsed from $174.5m to $23.7m, cutting receivable days from ~87 to ~10. Operating cash flow of $172.9m was, however, 38.9% below the HY25 figure of $282.8m.

The headline management claim — first positive free cash flow in over a decade of $56.2m — is the operational milestone framing this result.

What matters

1. The PBT swing is almost entirely fair value, not operating deterioration. The company's non-GAAP EBITDAF of $40.1m is the cleaner read on operating performance. HY25's $174.8m PBT was inflated by investment property fair value gains; HY26's $40.2m loss reflects their absence or partial reversal. Without a full reconciliation schedule in the disclosed materials, the precise quantum of fair value movements cannot be confirmed, but PBTF (profit before tax and fair value movements) is disclosed as a separate management metric for exactly this reason. The reported GAAP loss is real but heavily distorted by non-cash mark-to-market movements.

2. The balance sheet reset changes the risk profile materially. Gross borrowings falling $928m to $1.663b — partly through asset sales including the completion of facility disposals referenced in the release — reduces refinancing risk that has overhung the stock. At the same time, net debt of ~$1.654b against a half-year EBITDAF of $40.1m (annualised ~$80m) implies leverage that remains very high in absolute terms. The direction is the right one; the level is not yet comfortable.

3. OCF decline of $109m warrants scrutiny against the FCF milestone. The trade receivable release of ~$151m appears to have contributed meaningfully to prior-period OCF. HY26 OCF of $172.9m on a much smaller receivables balance may reflect a more normalised collections cycle. Nevertheless, OCF was $109m lower year-on-year, and the FCF positive result of $56.2m is partly a function of capex discipline rather than earnings improvement.

Expectations

No quantified FY26 guidance was disclosed. The company provides no earnings target against which to benchmark this result.

From prior-period seasonality, HY25 represented 48% of FY25 revenue and was the slightly lighter revenue half; HY26 annualises to approximately $827.6m, roughly $67m above FY25's $760.7m. On earnings shape, FY25 NPAT of -$436.8m was predominantly determined by a deeply negative second half (implied HY25 H2 loss of $531m), which was driven by large investment property write-downs rather than recurring operations. That makes year-on-year NPAT comparisons almost meaningless as a performance gauge.

The pricing model changes (average DMF uplift on ORA sales) and cost-out initiatives described as "tracking ahead of expectations" suggest the operating runway is improving, but neither is quantified in the disclosed materials. The first positive FCF milestone is meaningful against the decade-long context, though it is not directly comparable to any stated target.

Quality of result

The quality picture is mixed. Revenue growth of 13% looks durable — it reflects both occupancy recovery and embedded pricing changes rather than one-off items. EBITDAF of $40.1m is the operating heartbeat, and segment margins in New Zealand and Australia villages (~21% and ~23% respectively) are positive, though both appear materially below the prior-period segment contributions, suggesting either cost pressures or fair value allocation effects within the segment disclosures.

The FCF positive result has a material working capital component: the $151m receivables release contributed to historical OCF rather than HY26, but normalising the receivables base removes a structural drag on future cash conversion. Capex of $113.4m (27% of revenue) remains elevated and reflects ongoing development commitments; this constrains free cash durability.

The large GAAP loss is substantially non-cash (fair value movements), which reduces its relevance to operating quality assessment. The tax line adds modest noise — effective rate of 12% on a loss versus 46% on prior-period profit — but is not the dominant swing factor.

Overall: operating performance is improving modestly from a low base; the result is not high quality in the traditional sense (no dividend, loss-making at NPAT, elevated leverage), but the structural reset is advancing, and the FCF milestone is a genuine directional marker rather than an accounting artefact.

Unresolved

  • The full reconciliation of EBITDAF and PBTF to IFRS profit is not in the disclosed materials, making it impossible to confirm the exact quantum of investment property fair value movements that drove the PBT swing.
  • Segment EBITDAF margins appear to have declined sharply versus HY25 segment contributions, but no prior-period EBITDAF segment comparatives are disclosed, leaving the margin trajectory uncertain.
  • The $928m debt reduction appears partly asset-sale funded; the proceeds, assets disposed, and whether further disposals are planned are not quantified in the excerpts provided.
  • Cost-out initiatives are described as "ahead of expectations" but without a base, target, or dollar quantum, this cannot be stress-tested.
  • NZD/AUD translation exposure is material given the Australian segment, but no sensitivity or hedging position was disclosed.

This briefing cannot assess whether the improving EBITDAF trajectory is sufficient to service debt obligations and fund development commitments without further equity or asset disposals, as forward cash flow projections and covenant positions were not disclosed.

Key metrics

← Swipe to view more
Metric HY26 HY25 Change
Revenue $413.8m $366.3m +13.0% ↑
Net profit after tax −$45.2m $94.4m -147.9% ↓
Net cash inflow from operating activities $172.9m $282.8m -38.9% ↓
Profit before tax −$40.2m $174.8m -123.0% ↓
Cash and cash equivalents $8.9m $22.6m -60.5% ↓
Total assets $12149.6m $12814.9m -5.2% ↓

Source: annolyse.ai/briefings/rym-hy26

Segment breakdown

← Swipe to view more
Segment Current revenue Prior revenue Current result Mix shift
New Zealand villages $315.0m $283.1m $65.8m -1.2pp
Australia villages $97.3m $82.3m $22.6m +1.0pp
Non-village $1.2m $0.8m −$48.2m +0.1pp

Source: annolyse.ai/briefings/rym-hy26

Analytical metrics

← Swipe to view more
Metric HY26 HY25 Context
Effective tax rate n/m (loss period) 46.0% current loss period
OCF / EBITDAF (cash conversion) 430.9% deteriorated
FCF pre-lease $59.5m $178.9m −$119.4m
FCF post-lease $56.2m
FCF / NPAT -124.3% 189.6% complementary conversion metric
Capex % revenue 27.4% 28.4%
Capex $113.3m −$72.5m +$185.8m
Free cash flow $56.2m
Debtor days 10.4 86.8 -76.4 days
Inventory days 0.0 0.9 -0.9 days
Operating working capital $23.7m $176.4m −$152.7m absorbed
Trade debtors $23.7m $174.5m −$150.8m
Net debt $1653.7m $2568.5m −$914.7m
Net debt / EBITDAF 41.20x Strengthening
Gross borrowings $1662.7m $2591.1m −$928.4m
ROE (annualised) -1.1% 2.2% Weakening
HY25 share of FY25 revenue 48.1% Other half was 51.9%
HY25 share of FY25 NPAT -21.6% Other half was 121.6%

Source: annolyse.ai/briefings/rym-hy26


This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Appendix

Source documents

The filings and announcement documents considered in this briefing.

Current period

Ryman Healthcare Limited - Interim Financial Statements - 30 September 2025

HY26 / financial report

Ryman Healthcare Limited - Media Release - 30 September 2025

HY26 / media release

Prior comparable period

Ryman Healthcare Limited - Consolidated Interim Financial Statements - 30 September 2024

HY25 / financial report

Ryman Healthcare Limited - Media Release - 30 September 2024

HY25 / media release

Full-year context

Ryman Healthcare Limited - Announcement Numbers - 31 March 2025

FY25 / results release

Ryman Healthcare Limited - Consolidated Financial Statements - 31 March 2025

FY25 / financial report

Subscribe

Want briefings like this for the next reporting season?

Annolyse is being built as a publication product first. Subscribe for the next release.